Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S.

Cancer Lett. 2015 Feb 1;357(1):286-296. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20.

2.

Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.

Pathria G, Garg B, Borgdorff V, Garg K, Wagner C, Superti-Furga G, Wagner SN.

Cell Death Dis. 2016 Mar 10;7:e2135. doi: 10.1038/cddis.2015.369.

3.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z.

4.

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.

Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi ME, Conkrite KL, Asgharzadeh S, Seeger RC, Madison BB, Rustgi AK, Maris JM, Diskin SJ.

Cancer Cell. 2015 Nov 9;28(5):599-609. doi: 10.1016/j.ccell.2015.09.012. Epub 2015 Oct 17.

5.

Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.

Pathria G, Wagner C, Wagner SN.

J Invest Dermatol. 2012 Dec;132(12):2780-90. doi: 10.1038/jid.2012.233. Epub 2012 Jul 26.

6.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

7.

miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A.

Chang X, Zhang H, Lian S, Zhu W.

Biochem Biophys Res Commun. 2016 Jul 1;475(3):251-6. doi: 10.1016/j.bbrc.2016.05.090. Epub 2016 May 24.

PMID:
27233613
8.

The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.

Takahashi Y, Sheridan P, Niida A, Sawada G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y, Hase K, Kusunoki M, Kudo S, Watanabe M, Yamada K, Sugihara K, Yamamoto H, Suzuki A, Doki Y, Miyano S, Mori M, Mimori K.

Ann Oncol. 2015 May;26(5):935-42. doi: 10.1093/annonc/mdv034. Epub 2015 Jan 28.

PMID:
25632068
9.

RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression.

Yi M, Yang J, Chen X, Li J, Li X, Wang L, Tan Y, Xiong W, Zhou M, McCarthy JB, Li G, Xiang B, Xie H.

J Cell Physiol. 2011 Sep;226(9):2360-9. doi: 10.1002/jcp.22568.

10.

Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.

Bai J, Lei Y, An GL, He L.

PLoS One. 2015 Mar 16;10(3):e0121247. doi: 10.1371/journal.pone.0121247. eCollection 2015.

11.

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.

Yuen HF, Chan KK, Platt-Higgins A, Dakir el-H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2016 Nov 15;7(46):75854-75864. doi: 10.18632/oncotarget.12420.

12.

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, D'Atri S.

Biochem Pharmacol. 2012 Sep 1;84(5):598-611. doi: 10.1016/j.bcp.2012.06.004. Epub 2012 Jun 13.

PMID:
22704958
13.

Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma.

Liu S, Howell P, Ren S, Fodstad O, Zhang G, Samant R, Shevde L, Xi Y, Pannell LK, Riker AI.

Clin Exp Metastasis. 2009;26(7):739-49. doi: 10.1007/s10585-009-9273-8. Epub 2009 Jun 2.

PMID:
19488830
14.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
15.
16.

AEG-1 overexpression is essential for maintenance of malignant state in human AML cells via up-regulation of Akt1 mediated by AURKA activation.

Long M, Hao M, Dong K, Shen J, Wang X, Lin F, Liu L, Wei J, Liang Y, Yang J, Gu F, Zhang H.

Cell Signal. 2013 Jun;25(6):1438-46. doi: 10.1016/j.cellsig.2013.03.001. Epub 2013 Mar 14.

PMID:
23499911
17.

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions.

Fanale D, Bazan V, Corsini LR, Caruso S, Insalaco L, Castiglia M, Cicero G, Bronte G, Russo A.

Breast Cancer Res Treat. 2013 Aug;140(3):505-17. doi: 10.1007/s10549-013-2649-0. Epub 2013 Aug 8.

PMID:
23925655
18.

Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP.

Am J Pathol. 2013 Apr;182(4):1151-62. doi: 10.1016/j.ajpath.2012.12.019. Epub 2013 Feb 12.

19.

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U.

Blood. 2010 Sep 2;116(9):1498-505. doi: 10.1182/blood-2009-11-251074. Epub 2010 Jun 2.

20.

Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C.

J Biol Chem. 2012 Aug 24;287(35):29887-98. doi: 10.1074/jbc.M112.371682. Epub 2012 Jul 5.

Supplemental Content

Support Center